UNSPSC 51292911: Metapramine

This classification denotes an antidepressant agent with the molecular formula C16H18N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 303954M7YF, chemically known as 10,11-dihydro-5-methyl-10-(methylamino)-5h-dibenz(b,f)azepine but generally known as metapramine, which bears US NIH Compound Identifier 65700. European Medicines Agency schedules Metapramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08814MIG.

UNSPSC 51292911 Metapramine, a Commodity code, covers pharmaceutical products and related systems that state and local governments procure to support public health, emergency response, and community health initiatives. Recent state and local solicitations under this code show activity spanning naloxone and drug deactivation systems for emergency medical response, generic multi-source pharmaceuticals distributed through cooperative purchasing networks, and direct-to-manufacturer prescription programs designed to improve cost management and fulfillment efficiency. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP, serving Minnesota, Oregon, and other participants). Work ranges from competitive procurement of naloxone and harm-reduction equipment through county IFBs, to RFPs for generic pharmaceutical supply contracts serving state and local facilities, to exploratory RFIs mapping vendor capabilities for direct manufacturer relationships outside traditional pharmacy benefit manager channels.

Geographic activity concentrates in Florida, Texas, and Minnesota, with MMCAP's cooperative model extending across multiple states. Representative recent opportunities include Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (posted June 30, 2026, response due July 26, 2023), the Texas HHS Commission's RFI on direct-to-manufacturer prescription program capabilities (posted April 3, 2026, response due April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products requiring manufacturer participation with authorized wholesalers and compliance with cGMP and drug supply chain security standards (posted January 20, 2026, response due March 26, 2026, effective July 1, 2026). Contracts typically require E-Verify compliance, workers' compensation and liability insurance, FDA certification, and adherence to federal regulations including the Clean Air Act when federally funded; awards span fixed-fee and net-price models with administrative fees ranging from 3 percent to performance penalties of $200–$1,500 per violation.